A Critical Review of Properties and Analytical Methods for the Determination of Docetaxel in Biological and Pharmaceutical Matrices

被引:23
作者
da Silva, Gilmar Hanck [1 ]
Fernandes, Mariza Aires [1 ]
Fatori Trevizan, Lucas Noboru [1 ]
de Lima, Felipe Tita [1 ]
Eloy, Josimar O. [1 ]
Chorilli, Marlus [1 ]
机构
[1] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-14800903 Araraquara, SP, Brazil
关键词
Docetaxel; physicochemical properties; drug delivery systems; analytical methods; PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; UPLC-MS/MS METHOD; SOLID LIPID NANOPARTICLES; TARGETED CO-DELIVERY; RP-HPLC METHOD; HUMAN PLASMA; RAT PLASMA; LOADED NANOPARTICLES; ANTICANCER DRUGS;
D O I
10.1080/10408347.2018.1456315
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Docetaxel (DTX) is an antineoplastic agent of the second generation of the taxoid family. It is a semi-synthetic drug prepared from a precursor extracted of the plant Taxus baccata. The commercial formulation of DTX, Taxotere (R), employs the surfactant polysorbate 80, due to the low water solubility of the drug, causing several side effects. Therefore, there is a need to develop delivery systems to reduce the side effects of DTX. In addition, this drug has been qualitative and quantitatively analyzed in pharmaceutical formulations and biological samples. Thus, several techniques and analytical methods have been reported with the aim of optimizing the analytical signal, increasing sensitivity, selectivity and reducing the effects of interference. Herein, we highlight immunoassay, capillary electrophoresis and chromatographic methods. This review presents a summary of physicochemical and pharmacokinetics properties, mechanisms of action, drug delivery systems and analytical methods used in quantification of DTX in diverse matrices such as blood, plasma, oral fluid, urine, carcinoma cells, pharmaceutical formulations and delivery systems.
引用
收藏
页码:517 / 527
页数:11
相关论文
共 115 条
[1]   EARLY CLINICAL-STUDIES WITH DOCETAXEL [J].
AAPRO, M ;
BRUNO, R .
EUROPEAN JOURNAL OF CANCER, 1995, 31A :S7-S10
[2]   Anticancer drugs from nature - natural products as a unique source of new microtubule-stabilizing agents [J].
Altmann, Karl-Heinz ;
Gertsch, Juerg .
NATURAL PRODUCT REPORTS, 2007, 24 (02) :327-357
[3]  
Andersen Anders, 2006, BMC Clin Pharmacol, V6, P2, DOI 10.1186/1472-6904-6-2
[4]  
[Anonymous], 2009, ELECT J DIFFERENTIAL, DOI DOI 10.1371/J0URNAL.P0NE.0106787
[5]  
Arbuck S.G., 1995, TAXOL, P379
[6]  
Ardiet CJ, 1999, INVEST NEW DRUG, V17, P325
[7]   Pharmacogenetic Pathway Analysis of Docetaxel Elimination [J].
Baker, S. D. ;
Verweij, J. ;
Cusatis, G. A. ;
van Schaik, R. H. ;
Marsh, S. ;
Orwick, S. J. ;
Franke, R. M. ;
Hu, S. ;
Schuetz, E. G. ;
Lamba, V. ;
Messersmith, W. A. ;
Wolff, A. C. ;
Carducci, M. A. ;
Sparreboom, A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) :155-163
[8]   Clinical pharmalcokinetics of docetaxel - Recent developments [J].
Baker, SD ;
Sparreboom, A ;
Verweij, J .
CLINICAL PHARMACOKINETICS, 2006, 45 (03) :235-252
[9]   Relationship of systemic exposure to unbound docetaxel and neutropenia [J].
Baker, SD ;
Li, J ;
ten Tije, AJ ;
Figg, WD ;
Graveland, W ;
Verweij, J ;
Sparreboom, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) :43-53
[10]   Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry [J].
Baker, SD ;
Zhao, M ;
He, P ;
Carducci, MA ;
Verweij, J ;
Sparreboom, A .
ANALYTICAL BIOCHEMISTRY, 2004, 324 (02) :276-284